4D Molecular Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
4D Molecular Therapeutics, Inc. (FDMT) had Deferred Tax Assets, Operating Loss Carryforwards of $74.37 million as of 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-18
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $74.37M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $72.39M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $59.55M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $47.05M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $74.37M 10-K · filed 2026-03-18 |
| 2024-12-31 | $72.39M 10-K · filed 2026-03-18 |
| 2023-12-31 | $59.55M 10-K · filed 2025-02-28 |
| 2022-12-31 | $47.05M 10-K · filed 2024-02-29 |
| 2021-12-31 | $37.30M 10-K · filed 2023-03-15 |
| 2020-12-31 | $21.13M 10-K · filed 2022-03-28 |
| 2019-12-31 | $10.64M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |